Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Kalypsys, Alcon sign eye pact

January 9, 2006 | A version of this story appeared in Volume 84, Issue 2

Kalypsys and Alcon have entered a four-year pact to identify ophthalmic drug candidates to be developed and commercialized by Alcon. Kalypsys will use its ultra-high-throughput screening technology and chemical library, along with its medicinal chemistry expertise, to select and profile small molecules that are active against certain targets. Alcon will develop, manufacture, and commercialize any products that come out of the pact. Kalypsys says the deal is the first in an overall strategy to establish partnerships in several therapeutic fields over the next 12-18 months.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.